about
Affinity and avidity in antibody-based tumor targetingThe production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungiA New Twist in TCR Diversity Revealed by a Forbidden αβ TCRInteractions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing ActivitySynthetic approach to the generation of antibody diversityStructural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolitesDevelopment of genetically engineered human sperm immunocontraceptivesModulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.Recombinant antibodies: a novel approach to cancer diagnosis and therapy.Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development.Design and applications of bispecific heterodimers: molecular imaging and beyondBeyond natural antibodies: the power of in vitro display technologies.The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs.Engineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi.Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.Chemical generation of bispecific antibodies.Specificity of furanoside-protein recognition through antibody engineering and molecular modeling.A fully human scFv phage display library for rapid antibody fragment reformattingDevelopment of sandwich dot-ELISA for specific detection of Ochratoxin A and its application on to contaminated cereal grains originating from IndiascFv antibody: principles and clinical applicationSoluble Expression and Characterization of a New scFv Directed to Human CD123.Challenges in design and characterization of ligand-targeted drug delivery systems.Protein-based tumor molecular imaging probes.Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-lifeDevelopment of a novel small antibody that retains specificity for tumor targeting.Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamineDevelopment of active and passive human vaccines to treat methamphetamine addiction.Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.From rabbit antibody repertoires to rabbit monoclonal antibodiesExpression of recombinant antibodies.Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency.On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targetsMultimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers.Oligomeric forms of single chain immunoglobulin (scIgG).Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.
P2860
Q24613552-53525D4A-0EFE-441B-A306-598946FE7662Q24800574-D93F9FED-17B0-414D-9235-83CCD831D710Q27649399-268971B8-527D-4F33-B4ED-ED7B6DFAC74DQ27658138-0B985203-2497-4F4F-B809-008A6B797EBEQ28086872-EE3586FF-8557-4DF5-BACC-2080D52ACFA4Q28536667-2D976843-B612-4FF1-BEA7-F10145AED12EQ28749660-F1528B1B-16DF-4291-A9DC-9617A682FF0CQ31100421-9217DD81-D50F-450A-9025-8B4C90099E21Q33181384-73B98040-01E0-40A2-A8D5-F51DFA1A0C8AQ33326086-BA1A78CF-4EEB-43C6-B35A-74B685F258F3Q33732587-3FD7113D-4FF7-4296-B3E1-9923B808690BQ33841864-1E71DAD8-035E-416A-9DEA-975E04BC666CQ33846617-0CAC22FD-AAEA-4D1D-89E7-1B662181EF02Q33886121-E967908D-727C-4B91-A95A-A63D7CACC428Q33966998-93EF7CC6-2620-429E-A681-DBFF430751D2Q34450000-8E7853BC-99EB-4AB3-9B5E-C9618148D359Q34861376-69F31F11-BDD7-4C46-A19B-DBBE657C81FAQ35635839-849BC0C8-D236-4EFC-A004-A1FA473334F7Q35644330-5EA18BB2-E22E-461A-B221-62C2D03220F9Q35852647-45D38B23-A432-4430-9C8D-9CCD937BE40EQ35889617-4F760A26-7BEB-423A-A5A2-716C83786299Q36346851-8B44EFD3-9992-4935-B1CE-A01A34DE91E6Q36742911-660B2344-48B5-42F3-AB86-E70972928058Q36953914-4709E8D2-E316-45B7-BDBC-1CB2FA607E3AQ37211010-065F8CFC-6048-4C94-8590-0994219309FDQ37411538-E9F62F65-B8A4-402D-914B-9D7BD61DF199Q37411959-6BC9647D-8381-44AC-BD02-2A1359E88242Q37545105-343F7C9A-3BAA-4A6A-80B3-9E302ECDD360Q37739483-B86BB7A1-97F7-41E9-8ABE-B8EB66D9FDB2Q38126016-126A8929-9141-46AB-B8E1-538C99E575A6Q38139218-9886F786-76AF-4CB4-A13F-592A71B9C04EQ38289992-FCEFC5E3-4B25-4CFB-9730-11B48A766214Q38369824-9587C50E-4012-411D-827C-C6FA058C1D63Q38710840-120EECFE-6B0B-4968-BF1D-85EA96375B9FQ39119871-BBDE606C-47B0-4D81-80BC-9174194608C5Q39276067-2C277ABA-B5D2-48A9-A6CB-CFCAE39922B6Q39428042-18EFBC16-A961-4282-9FEF-4E3E2A61717AQ39786582-7D8EBD16-FB32-4B61-B0D1-BE4D5ACD694EQ40114596-2EC37BC7-0EAA-4C13-9841-8C6AD8A9A4A6Q40233745-04B216F0-070D-4F79-9A71-7713B38B3724
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
High avidity scFv multimers; diabodies and triabodies.
@ast
High avidity scFv multimers; diabodies and triabodies.
@en
type
label
High avidity scFv multimers; diabodies and triabodies.
@ast
High avidity scFv multimers; diabodies and triabodies.
@en
prefLabel
High avidity scFv multimers; diabodies and triabodies.
@ast
High avidity scFv multimers; diabodies and triabodies.
@en
P1476
High avidity scFv multimers; diabodies and triabodies.
@en
P2093
P304
P356
10.1016/S0022-1759(99)00157-X
P577
1999-12-01T00:00:00Z